Page 5 - Beckley Psytech News Today

The truth is always stranger than fiction, and once thats the case for this past week.

A psychedelic toad compound is being used as a potential treatment for alcoholism.

London researchers to assess possible therapeutic benefits of new synthetic drug made from mebufotenin

Open-label study will investigate the safety, efficacy and pharmacokinetics of BPL-003 in patients diagnosed with alcohol use disorder (AUD). BPL-003 is Beckley Psytech's patent-protected

Private psychedelics companies have raised hundreds of millions of dollars. Here are the biggest venture investors backing their efforts.

This is the first time the FDA has given IND approval for a Phase IIb study of a short-acting psychedelic like 5-MeO-DMT (Mebufotenin). Beckley Psytech plans to initiate a global multi-site

Beckley Psytech Ltd, a private, clinical-stage biotechnology company dedicated to addressing neuropsychiatric disorders by transforming psychedelics into safe, effective and licensed medicines, today announced that it had received Investigational New Drug (IND) approval from the U.S. Food and Drug Administration ...

The antipsychotic drugs market is expanding rapidly due to the increasing prevalence of mental disorders such as schizophrenia, schizoaffective disorder,...

The antipsychotic drugs market is expanding rapidly due to the increasing prevalence of mental disorders such as schizophrenia, schizoaffective disorder, bipolar disorder, severe depression

Canada: Fed Guidelines For Psychedelic Therapy, Quebec Treatment Costs, Access And Magic Mushrooms Dispensaries The agency regulating all things ...